(Q37848271)

24 August 2017

1 reference

title

When to start an aromatase inhibitor: now or later? (English)

1 reference

24 August 2017

Julie C Doughty

1

1 reference

24 August 2017

publication date

24 February 2011

1 reference

Journal of Surgical Oncology

24 August 2017

published in

1 reference

24 August 2017

volume

103

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

730-738

1 reference

Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer

24 August 2017

cites work

1 reference

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

21 January 2018

1 reference

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

21 January 2018

1 reference

Quality of life of breast cancer survivors after a recurrence: a follow-up study

21 January 2018

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen

21 January 2018

1 reference

Early discontinuation of tamoxifen: a lesson for oncologists.

21 January 2018

1 reference

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

Meta-analysis of vascular and neoplastic events associated with tamoxifen

21 January 2018

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

21 January 2018

1 reference

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer

21 January 2018

1 reference

Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels

21 January 2018

1 reference

An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples

21 January 2018

1 reference

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole

21 January 2018

1 reference

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

21 January 2018

1 reference

Refining the postmenopausal breast cancer treatment paradigm: the FACE trial

21 January 2018

1 reference

Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen

21 January 2018

1 reference

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

21 January 2018

1 reference

Practical guidance for the management of aromatase inhibitor-associated bone loss

21 January 2018

1 reference

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.

21 January 2018

1 reference

Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer

21 January 2018

1 reference

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden.

21 January 2018

1 reference

Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.

21 January 2018

1 reference

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JSO.21801

1 reference

24 August 2017

1 reference